A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Clinical trial NCT07293351 · RECRUITING
Trial details
- NCT number
- NCT07293351
- Sponsor
- Bristol-Myers Squibb
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-26
- Primary completion
- 2029-11-28
- Enrollment
- 254
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.